Hostname: page-component-5c6d5d7d68-wpx84 Total loading time: 0 Render date: 2024-08-22T01:48:53.065Z Has data issue: false hasContentIssue false
  • English
  • Français

Anakinra as rescue therapy for steroid-dependent idiopathic recurrent pericarditis in children: case report and literature review

Published online by Cambridge University Press:  04 December 2018

Moises Rodriguez-Gonzalez Open the ORCID record for Moises Rodriguez-Gonzalez [Opens in a new window] ,
Estefania Ruiz-Gonzalez  and
Ana Castellano-Martinez
Moises Rodriguez-Gonzalez*
Affiliation:
Pediatric Cardiology Department, Hospital Universitario Puerta del Mar, Cadiz, Spain
Estefania Ruiz-Gonzalez
Affiliation:
Pediatrics Department, Hospital Universitario Puerta del Mar, Cadiz, Spain
Ana Castellano-Martinez
Affiliation:
Pediatric Nephrology Department, Puerta del Mar University Hospital, Cadiz, Spain
*
Author for correspondence: M. Rodriguez-Gonzalez, Department of Pediatric Cardiology, Puerta del Mar University Hospital, Ana de Viya Avenue 34, 11009 Cadiz, Spain. Tel: 34 956002700; Fax: 34 956002085; E-mail: moirogo@gmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

In approximately 5% of patients with idiopathic recurrent pericarditis, the disease usually follows a chronic relapsing course, and children can develop dependence and side effects of prolonged high-dose corticosteroid regimens. In this setting anakinra, a recombinant human interleukin-1 competitive receptor antagonist that blocks the biologic effects of interleukin-1, thereby reducing systemic inflammatory responses, appears to be one of the most promising strategies. We report an adolescent with steroid-dependent idiopathic recurrent pericarditis that was successfully treated with anakinra, highlighting that this therapeutic option seems to be an effective, rapidly acting, steroid-sparing, and relatively safe agent for the treatment of this entity in children.

Keywords

Recurrent pericarditisanakinrainterleukin-1 receptor antagonistchildrenauto-inflammatory disease
Type
Brief Report
Information
Cardiology in the Young , Volume 29 , Issue 2 , February 2019 , pp. 241 - 243
Copyright
© Cambridge University Press 2018 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Cite this article: Rodriguez-Gonzalez M, Ruiz-Gonzalez E, Castellano-Martinez A. (2018) Anakinra as rescue therapy for steroid-dependent idiopathic recurrent pericarditis in children: case report and literature review. Cardiology in the Young page 241 of 243. doi: 10.1017/S1047951118002020

References

1. Imazio, M, Brucato, A, Pluymaekers, N, et al. Recurrent pericarditis in children and adolescents. J Cardiovasc Med 2016; 17: 707–712.Google Scholar
2. Lazaros, G, Antonatou, K, Vassilopoulos, D. The therapeutic role of interleukin-1 inhibition in idiopathic recurrent pericarditis: current evidence and future challenges. Front Med 2017; 4: 99–106.Google Scholar
3. Cantarini, L, Lopalco, G, Selmi, C, et al. Autoimmunity and autoinflammation as the yin and yang of idiopathic recurrent acute pericarditis. Autoimmun Rev 2015; 14: 90–97.Google Scholar
4. Scott, IC, Hajela, V, Hawkins, PN, Lachmann, HJ. A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis. J Cardiol Cases 2011; 4: e93–e97.Google Scholar
5. Picco, P, Brisca, G, Traverso, F, Loy, A, Gattorno, M, Martini, A. Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease? Arthritis Rheum 2009; 60: 264–268.Google Scholar
6. Scardapane, A, Brucato, A, Chiarelli, F, Breda, L. Efficacy of an interleukin-1β receptor antagonist (anakinra) in idiopathic recurrent pericarditis. Pediatr Cardiol 2012; 34: 1989–1991.Google Scholar
7. Murias Loza, S, García-Guereta Silva, L, Alcobendas Rueda, RM, Remesal Camba, A. Eficacia de anakinra como tratamiento de la pericarditis recurrente. Anales de Pediatría 2018; 88: 223–224.Google Scholar
8. Finetti, M, Insalaco, A, Cantarini, L, et al. Long-term efficacy of interleukin-1 receptor antagonist (anakinra) in corticosteroid-dependent and colchicine-resistant recurrent pericarditis. J Pediatr 2014; 164: 1425–31.e1.Google Scholar
9. Brucato, A, Imazio, M, Gattorno, M, et al. Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence. J Am Med Assoc 2016; 316: 1906–1907.Google Scholar
10. Alraies, MC, AlJaroudi, W, Yarmohammadi, H, et al. Usefulness of cardiac magnetic resonance-guided management in patients with recurrent pericarditis. Am J Cardiol 2015; 115: 542–547.Google Scholar